Radius Health, Inc. (NASDAQ:RDUS) headquartered in Waltham, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.radiuspharm.com
Earnings Expectation
Radius Health, Inc. is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, RDUS is expected to report 2Q20 loss of $ 0.74 per share from revenue of $ 47.40 million. For the full year, analysts anticipate top line of $ 217.92 million, while looking forward to loss of $ 2.42 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 190.00 million ~ $ 220.00 million
Click Here For More Historical Outlooks Of Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
